Trial reportMolecular therapy : the journal of the American Society of Gene Therapy2025
Lyophilized apoptotic vesicles improve hemostasis and bone regeneration in traumatic patients with impacted third molar extraction.
Trial report in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- Therapeutic potential of mesenchymal stem cell-derived apoptotic vesicles in liver fibrosis: targeting the IGFBP3/PI3K-AKT axis via miR-409-3p.Stem cell research & therapy · 2026Article
- Eosinophil-derived apoptotic extracellular vesicles accelerate steatotic liver repair after ischemia/reperfusion injury through mitochondria-associated metabolic reprogramming.Journal of nanobiotechnology · 2026Article
- Review
- Fuel to fire: developmental niche-empowered ApoEVs unlock adult hierarchical tissue regenerative potential via mitochondrial complex I-driven developmental metabolic profile.International journal of oral science · 2026Article
- Apoptotic extracellular vesicles act as master regulators of the bone healing niche.Journal of nanobiotechnology · 2026Review
- Apoptotic vesicles: from biological characteristics to clinical translational prospects.Journal of translational medicine · 2026Review
- Mesenchymal stem cells-derived extracellular vesicles as a novel drug delivery carrier: engineering strategies and clinical safety estimation.Frontiers in molecular biosciences · 2026Review
- Tissue regeneration strategies based on mesenchymal stem cell-derived extracellular vesicles: from bench to bedside.Burns & trauma · 2026Review
- Stability Challenges and Engineering Strategies of Plant-Derived Extracellular Vesicle-Like Particles: A Translational Perspective.International journal of nanomedicine · 2026Review
- Mesenchymal stem cell-derived apoptotic vesicles: emerging cell-free strategy for periodontitis treatment.Journal of nanobiotechnology · 2025Review
- Mesenchymal stem cells undergoing apoptosis recover cyclophosphamide-induced cleft palate through modulation of NLR signaling mediated pyroptosis.Stem cell research & therapy · 2025Article
- Review
- Mapping the Landscape of Mesenchymal Stem Cell-Derived Extracellular Vesicles: From Bench to Bedside.Stem cells international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uncontrollable bleeding and tissue defects caused by trauma are significant clinical issues. Apoptotic vesicles (apoVs) derived from mesenchymal stem cells (MSCs) have shown promise for hemostasis and tissue regeneration, but their clinical safety and efficacy remain unverified. We investigated the procoagulant and regenerative function of lyophilized MSC-derived apoVs (MSC-apoVs) using in vitro experiments and in vivo rat models. In addition, we conducted a double-blind, randomized, self-controlled clinical trial to evaluate the safety and efficiency of lyophilized MSC-apoVs for hemostasis and bone regeneration following extraction of impacted mandibular third molars. We show that lyophilized MSC-apoVs maintain their procoagulant and regenerative functions after storage at 4°C for 3 months and upregulate tripartite motif containing 71 to activate the extracellular signal-regulated kinase signaling pathway. Furthermore, among the 43 enrolled subjects, 39 patients completed all follow-ups and 4 patients were lost to contact. All 39 patients tolerated MSC-apoVs well, with no serious adverse events or abnormal blood test results observed. The MSC-apoV group exhibited shortened hemostatic time and accelerated alveolar bone regeneration compared with the control group. This is the first clinical study to demonstrate that apoVs are safe, well tolerated, and effective as a cell-free biological therapy for hemostasis and bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.